secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0000950170-24-076222
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx stockholders approve amended 2023 incentive plan and elect directors at annual meeting
--------------------------------------------------------------------------------

- Class II directors Dunsire, Narachi, and Sanders elected with over 66M votes each for terms until 2027.
- Amended 2023 Incentive Plan approved: 51.9M for, 22.3M against; adds 8.5M shares plus prior plan rollover shares.
- Ernst & Young ratified as independent auditor for FY2024 with 77.2M votes for (98.2% of votes cast).
- Advisory vote on executive compensation passed with 54.8M for vs 19.3M against; 4.3M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024076222/0000950170-24-076222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024076222/rare-20240618.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-076222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer